The Effect Of Lifitegrast On Refractive Accuracy And Symptoms In Dry Eye Patients Undergoing Cataract Surgery

Exclusion Criteria

• •1. Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgical procedure
• •2. Clinically significant ocular trauma.
• •3. Active ocular Herpes simplex or Herpes Zoster infection
• •4. Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator.
• •5. Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye).
• •6. Active, systemic or local disease condition that causes clinically significant ocular surface irritation such that it could interfere with the questions in the survey and examination findings.
• •7. Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis.
• •8. Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
• •9. Eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis).
• •10. Ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
• •11. Participation in another ophthalmic clinical trial involving a therapeutic drug or device within 30 days prior to enrollment date.
• •12. Participation in this trial in the same patient's fellow eye
• •13. Patients who are pregnant or breastfeeding or who may become pregnant during participation in the study.